PF-AtlasClinical Trials › NCT04279197

Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu

Fuzheng Huayu Tablet · Phase 2

Registry ID
NCT04279197
Phase
Phase 2
Status
Completed
Drug / intervention
Fuzheng Huayu Tablet
Sponsor
ShuGuang Hospital
Start
2020-04-23

About this trial

Fuzheng Huayu Tablet is evaluated in NCT04279197, a Phase 2 idiopathic pulmonary fibrosis study sponsored by ShuGuang Hospital. Current status: Completed.

View NCT04279197 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT04279197 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.